Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Terminated2
Recruiting1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04158141Phase 3Terminated

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT07121374Phase 1RecruitingPrimary

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

NCT02399371Phase 2Active Not Recruiting

Pembrolizumab in Treating Patients With Malignant Mesothelioma

NCT02672033Not ApplicableTerminatedPrimary

Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma

Showing all 4 trials

Research Network

Activity Timeline